BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun Y, Wang S, Yang H, Wu J, Li S, Qiao G, Wang S, Wang X, Zhou X, Osada T, Hobeika A, Morse MA, Ren J, Lyerly HK. Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. Immunotherapy 2019;11:953-66. [PMID: 31192764 DOI: 10.2217/imt-2019-0055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dunai C, Ames E, Ochoa MC, Fernandez-sendin M, Melero I, Simonetta F, Baker J, Alvarez M. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. Adoptive Cell Transfer 2022. [DOI: 10.1016/bs.ircmb.2022.04.001] [Reference Citation Analysis]
2 Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 2021;9:1075. [PMID: 34572263 DOI: 10.3390/biomedicines9091075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
3 Batista-Duharte A, Pera A, Aliño SF, Solana R. Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects. Int Immunopharmacol 2021;96:107761. [PMID: 34162139 DOI: 10.1016/j.intimp.2021.107761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lundstrom K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses 2020;12:E1324. [PMID: 33218001 DOI: 10.3390/v12111324] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
5 Crosby EJ, Hobeika AC, Niedzwiecki D, Rushing C, Hsu D, Berglund P, Smith J, Osada T, Gwin Iii WR, Hartman ZC, Morse MA, Lyerly HK. Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. J Immunother Cancer 2020;8:e001662. [PMID: 33177177 DOI: 10.1136/jitc-2020-001662] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
6 Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 2020;13:29. [PMID: 32245497 DOI: 10.1186/s13045-020-00862-w] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 36.5] [Reference Citation Analysis]